
Cellino is building an ultra-scalable biomanufacturing technology stack for personalized cell and tissue replacement therapies. Cellino’s vision is to enable healthier lives worldwide with personalized treatments derived from induced pluripotent stem cells (iPSCs), which can serve as the basis for therapies for a host of chronic degenerative diseases, including vision loss and Parkinson's disease.

Cellino is building an ultra-scalable biomanufacturing technology stack for personalized cell and tissue replacement therapies. Cellino’s vision is to enable healthier lives worldwide with personalized treatments derived from induced pluripotent stem cells (iPSCs), which can serve as the basis for therapies for a host of chronic degenerative diseases, including vision loss and Parkinson's disease.
Headquarters: Cambridge, Massachusetts
Core product: Nebula™ AI-driven automated optical biomanufacturing platform for iPSC-derived therapies
Focus: Personalized regenerative cell, tissue, and organ replacements from patient iPSCs
Notable funding: $16M seed (2021); $80M Series A (2022); ARPA-H grant (2024)
Employee count: 133
Scalable manufacturing bottleneck for personalized regenerative cell and tissue therapies derived from iPSCs.
Biotechnology Research
$16 million
$80 million
Awarded grant from Advanced Research Projects Agency for Health
“Leaps by Bayer, Khosla Ventures, The Engine, Felicis, 8VC, Humboldt Fund”